US10323236B2
(en)
|
2011-07-22 |
2019-06-18 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
RU2656156C2
(en)
|
2011-10-17 |
2018-05-31 |
Массачусетс Инститьют Оф Текнолоджи |
Intracellular delivery
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
CA2921579C
(en)
|
2013-08-16 |
2021-09-21 |
Massachusetts Institute Of Technology |
Selective delivery of material to cells
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
US9737604B2
(en)
|
2013-09-06 |
2017-08-22 |
President And Fellows Of Harvard College |
Use of cationic lipids to deliver CAS9
|
KR102380245B1
(en)
|
2013-11-07 |
2022-03-30 |
에디타스 메디신, 인코포레이티드 |
CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS
|
US11053481B2
(en)
|
2013-12-12 |
2021-07-06 |
President And Fellows Of Harvard College |
Fusions of Cas9 domains and nucleic acid-editing domains
|
WO2016011210A2
(en)
|
2014-07-15 |
2016-01-21 |
Juno Therapeutics, Inc. |
Engineered cells for adoptive cell therapy
|
EP3177718B1
(en)
|
2014-07-30 |
2022-03-16 |
President and Fellows of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
RU2020139190A
(en)
|
2014-10-31 |
2021-01-26 |
Массачусетс Инститьют Оф Текнолоджи |
DELIVERY OF BIOMOLECULES INTO THE CELLS OF THE IMMUNE SYSTEM
|
EA201790953A1
(en)
|
2014-10-31 |
2017-10-31 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
CHANGES IN THE EXPRESSION OF GENE IN CART-CELLS AND THEIR APPLICATION
|
CA2964138C
(en)
|
2014-11-14 |
2023-11-14 |
Massachusetts Institute Of Technology |
Disruption and field enabled delivery of compounds and compositions into cells
|
WO2016094880A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
|
WO2016094874A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Escorted and functionalized guides for crispr-cas systems
|
EP3889260A1
(en)
|
2014-12-12 |
2021-10-06 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
AU2015369725A1
(en)
|
2014-12-24 |
2017-06-29 |
Massachusetts Institute Of Technology |
CRISPR having or associated with destabilization domains
|
US11125739B2
(en)
|
2015-01-12 |
2021-09-21 |
Massachusetts Institute Of Technology |
Gene editing through microfluidic delivery
|
WO2016154596A1
(en)
*
|
2015-03-25 |
2016-09-29 |
Editas Medicine, Inc. |
Crispr/cas-related methods, compositions and components
|
IL302341A
(en)
*
|
2015-03-27 |
2023-06-01 |
Harvard College |
Modified t cells and methods of making and using the same
|
AU2016261600B2
(en)
|
2015-05-08 |
2021-09-23 |
President And Fellows Of Harvard College |
Universal donor stem cells and related methods
|
AU2016262521A1
(en)
*
|
2015-05-11 |
2017-12-14 |
Editas Medicine, Inc. |
CRISPR/CAS-related methods and compositions for treating HIV infection and AIDS
|
CA2986310A1
(en)
*
|
2015-05-11 |
2016-11-17 |
Editas Medicine, Inc. |
Optimized crispr/cas9 systems and methods for gene editing in stem cells
|
WO2016196388A1
(en)
|
2015-05-29 |
2016-12-08 |
Juno Therapeutics, Inc. |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
US11911415B2
(en)
|
2015-06-09 |
2024-02-27 |
Editas Medicine, Inc. |
CRISPR/Cas-related methods and compositions for improving transplantation
|
WO2016205749A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
CN107922911A
(en)
|
2015-07-09 |
2018-04-17 |
麻省理工学院 |
Material is delivered to cytode
|
MA42895A
(en)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
MODIFIED CELLS FOR ADOPTIVE CELL THERAPY
|
US10906951B2
(en)
|
2015-07-29 |
2021-02-02 |
Onk Therapeutics Limited |
Modified natural killer cells and natural killer cell lines having increased cytotoxicity
|
EP3317401B1
(en)
|
2015-07-29 |
2018-10-03 |
Onkimmune Limited |
Modified natural killer cells and natural killer cell lines having increased cytotoxicity
|
EP3328399B1
(en)
|
2015-07-31 |
2023-12-27 |
Regents of the University of Minnesota |
Modified cells and methods of therapy
|
EP3344575B1
(en)
|
2015-09-04 |
2020-04-15 |
SQZ Biotechnologies Company |
Intracellular delivery of biomolecules to cells comprising a cell wall
|
CA3002827A1
(en)
|
2015-10-23 |
2017-04-27 |
President And Fellows Of Harvard College |
Nucleobase editors and uses thereof
|
AU2016343991B2
(en)
*
|
2015-10-30 |
2022-12-01 |
Editas Medicine, Inc. |
CRISPR/CAS-related methods and compositions for treating herpes simplex virus
|
EP3384027A1
(en)
*
|
2015-12-04 |
2018-10-10 |
Novartis AG |
Compositions and methods for immunooncology
|
EP3402890A1
(en)
*
|
2016-01-12 |
2018-11-21 |
SQZ Biotechnologies Company |
Intracellular delivery of complexes
|
WO2017147278A1
(en)
|
2016-02-25 |
2017-08-31 |
The Children's Medical Center Corporation |
Customized class switch of immunoglobulin genes in lymphoma and hybridoma by crispr/cas9 technology
|
CA3016331A1
(en)
*
|
2016-03-04 |
2017-09-08 |
Editas Medicine, Inc. |
Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
|
EP3219799A1
(en)
|
2016-03-17 |
2017-09-20 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Conditional crispr sgrna expression
|
JP2019512271A
(en)
*
|
2016-03-21 |
2019-05-16 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
T cell exhaustion state specific gene expression regulator and use thereof
|
BR112018071439A2
(en)
*
|
2016-04-22 |
2019-03-19 |
Intellia Therapeutics, Inc. |
compositions and methods for treating diseases associated with three nucleotide repeats at transcription factor four
|
CN107304434A
(en)
*
|
2016-04-25 |
2017-10-31 |
上海宇玫博生物科技有限公司 |
A kind of difunctional novel carriers of immune cell therapy
|
JP2019517788A
(en)
*
|
2016-05-06 |
2019-06-27 |
ジュノー セラピューティクス インコーポレイテッド |
Genetically engineered cells and methods of making same
|
CA3022319A1
(en)
*
|
2016-05-06 |
2017-11-09 |
Tod M. Woolf |
Improved methods for genome editing with and without programmable nucleases
|
EP3476865B1
(en)
|
2016-06-28 |
2023-09-13 |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. |
Method for constructing pd-1 gene-modified humanized animal model and use thereof
|
JP7193862B2
(en)
*
|
2016-08-03 |
2022-12-21 |
ワシントン・ユニバーシティ |
Gene editing of CAR-T cells for the treatment of T-cell malignancies with chimeric antigen receptors
|
IL308426A
(en)
|
2016-08-03 |
2024-01-01 |
Harvard College |
Adenosine nucleobase editors and uses thereof
|
US11078481B1
(en)
|
2016-08-03 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for screening for cancer targets
|
CN109804066A
(en)
|
2016-08-09 |
2019-05-24 |
哈佛大学的校长及成员们 |
Programmable CAS9- recombination enzyme fusion proteins and application thereof
|
IL264439B1
(en)
*
|
2016-08-17 |
2024-04-01 |
Factor Bioscience Inc |
non-viral, cell-free composition comprising a synthetic messenger RNA (MRNA) encoding a gene-editing protein for use in treating cancer, and a synthetic RNA encoding a gene-editing protein for use in treatment
|
WO2018035388A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
US11078483B1
(en)
|
2016-09-02 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for measuring and improving CRISPR reagent function
|
EP3519433A1
(en)
|
2016-10-03 |
2019-08-07 |
Juno Therapeutics, Inc. |
Hpv-specific binding molecules
|
WO2018071873A2
(en)
|
2016-10-13 |
2018-04-19 |
Juno Therapeutics, Inc. |
Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
|
WO2018071868A1
(en)
|
2016-10-14 |
2018-04-19 |
President And Fellows Of Harvard College |
Aav delivery of nucleobase editors
|
GB2605540B
(en)
|
2016-10-18 |
2022-12-21 |
Univ Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
GB2607227B
(en)
*
|
2016-10-27 |
2023-05-10 |
Intima Bioscience Inc |
Viral methods of T cell therapy
|
US11332713B2
(en)
|
2016-11-16 |
2022-05-17 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
AU2017364806A1
(en)
*
|
2016-11-28 |
2019-06-13 |
Napajen Pharma, Inc. |
Chemically-modified siRNA
|
AU2017370644A1
(en)
|
2016-12-05 |
2019-06-13 |
Juno Therapeutics, Inc. |
Production of engineered cells for adoptive cell therapy
|
JP7206214B2
(en)
|
2016-12-13 |
2023-01-17 |
シアトル チルドレンズ ホスピタル (ディービーエイ シアトル チルドレンズ リサーチ インスティテュート) |
Methods for exogenous drug activation of chemo-inducible signaling complexes expressed in engineered cells in vitro and in vivo
|
US10745677B2
(en)
|
2016-12-23 |
2020-08-18 |
President And Fellows Of Harvard College |
Editing of CCR5 receptor gene to protect against HIV infection
|
JP2020503043A
(en)
*
|
2016-12-30 |
2020-01-30 |
セルラリティ インコーポレイテッド |
Genetically modified natural killer cells
|
WO2018140890A1
(en)
*
|
2017-01-29 |
2018-08-02 |
Zequn Tang |
Methods of immune modulation against foreign and/or auto antigens
|
TW201839136A
(en)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
Compositions and methods for the treatment of hemoglobinopathies
|
US10828330B2
(en)
*
|
2017-02-22 |
2020-11-10 |
IO Bioscience, Inc. |
Nucleic acid constructs comprising gene editing multi-sites and uses thereof
|
US11898179B2
(en)
|
2017-03-09 |
2024-02-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
EP3592777A1
(en)
|
2017-03-10 |
2020-01-15 |
President and Fellows of Harvard College |
Cytosine to guanine base editor
|
US11851659B2
(en)
|
2017-03-22 |
2023-12-26 |
Novartis Ag |
Compositions and methods for immunooncology
|
CA3057192A1
(en)
|
2017-03-23 |
2018-09-27 |
President And Fellows Of Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
WO2018191490A1
(en)
*
|
2017-04-13 |
2018-10-18 |
The Trustees Of The University Of Pennsylvania |
Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
BR112019023608A2
(en)
|
2017-05-12 |
2020-05-26 |
Crispr Therapeutics Ag |
MATERIALS AND METHODS FOR HANDLED CELLS AND THEIR USES IN IMMUNO-ONCOLOGY
|
US10428319B2
(en)
|
2017-06-09 |
2019-10-01 |
Editas Medicine, Inc. |
Engineered Cas9 nucleases
|
EP3638317A4
(en)
|
2017-06-15 |
2021-03-17 |
The Regents of The University of California |
Targeted non-viral dna insertions
|
AU2018288048A1
(en)
*
|
2017-06-20 |
2019-12-19 |
Jiangsu Hengrui Medicine Co., Ltd. |
Method for knocking out target gene in T cell in vitro and crRNA used in the method
|
SG10201705285SA
(en)
*
|
2017-06-27 |
2019-01-30 |
Agency Science Tech & Res |
Antisense oligonucleotides
|
WO2019003193A1
(en)
*
|
2017-06-30 |
2019-01-03 |
Novartis Ag |
Methods for the treatment of disease with gene editing systems
|
EP3645021A4
(en)
|
2017-06-30 |
2021-04-21 |
Intima Bioscience, Inc. |
Adeno-associated viral vectors for gene therapy
|
CN111801345A
(en)
|
2017-07-28 |
2020-10-20 |
哈佛大学的校长及成员们 |
Methods and compositions using an evolved base editor for Phage Assisted Continuous Evolution (PACE)
|
EP3676376A2
(en)
|
2017-08-30 |
2020-07-08 |
President and Fellows of Harvard College |
High efficiency base editors comprising gam
|
EP3684408A1
(en)
|
2017-09-19 |
2020-07-29 |
Massachusetts Institute of Technology |
Compositions for chimeric antigen receptor t cell therapy and uses thereof
|
KR20200104284A
(en)
|
2017-10-03 |
2020-09-03 |
주노 쎄러퓨티크스 인코퍼레이티드 |
HPV-specific binding molecule
|
WO2019072241A1
(en)
|
2017-10-13 |
2019-04-18 |
Beijing Biocytogen Co., Ltd |
Genetically modified non-human animal with human or chimeric pd-1
|
KR20200121782A
(en)
|
2017-10-16 |
2020-10-26 |
더 브로드 인스티튜트, 인코퍼레이티드 |
Uses of adenosine base editor
|
WO2019084552A1
(en)
|
2017-10-27 |
2019-05-02 |
The Regents Of The University Of California |
Targeted replacement of endogenous t cell receptors
|
WO2019089982A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
CN111556893A
(en)
*
|
2017-11-06 |
2020-08-18 |
爱迪塔斯医药股份有限公司 |
Methods, compositions, and components for CRISPR-CAS9 editing of CBLB in immunotherapy T cells
|
CN111655292A
(en)
*
|
2017-12-07 |
2020-09-11 |
旗舰先锋创新V股份有限公司 |
Cellular biologicals and therapeutic uses thereof
|
WO2019118508A1
(en)
|
2017-12-12 |
2019-06-20 |
The Trustees Of The University Of Pennsylvania |
Genetically modified immune cells targeting ny-eso-1 and methods of use thereof
|
EP3724327A4
(en)
*
|
2017-12-14 |
2022-01-12 |
EZY Biotech LLC |
Subject-specific tumor inhibiting cells and the use thereof
|
DK3765615T3
(en)
|
2018-03-14 |
2023-08-21 |
Arbor Biotechnologies Inc |
NEW ENZYMES AND SYSTEMS FOR TARGETING CRISPR DNA
|
US20190284553A1
(en)
|
2018-03-15 |
2019-09-19 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
AU2019234926A1
(en)
|
2018-03-15 |
2020-10-08 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
US20210017249A1
(en)
|
2018-04-05 |
2021-01-21 |
Juno Therapeutics, Inc. |
Methods of producing cells expressing a recombinant receptor and related compositions
|
KR20210020873A
(en)
|
2018-04-05 |
2021-02-24 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Τ cells expressing recombinant receptors, related polynucleotides and methods
|
MA52193A
(en)
|
2018-04-05 |
2021-02-17 |
Juno Therapeutics Inc |
T-LYMPHOCYTE RECEPTORS AND MODIFIED CELLS EXPRESSING THEM
|
EP3775213A1
(en)
*
|
2018-04-13 |
2021-02-17 |
Sigma Aldrich Co. LLC |
Modification of immune-related genomic loci using paired crispr nickase ribonucleoproteins
|
JP2021522820A
(en)
|
2018-05-11 |
2021-09-02 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
Methods and compositions for treating cancer
|
CN108866004A
(en)
*
|
2018-06-26 |
2018-11-23 |
奥妙生物技术(广州)有限公司 |
The T cell and its construction method that SHP-1 is knocked out
|
US20210317406A1
(en)
*
|
2018-07-09 |
2021-10-14 |
The Regents Of The University Of California |
Gene targets for t-cell-based immunotherapy
|
WO2020022802A1
(en)
*
|
2018-07-25 |
2020-01-30 |
주식회사 툴젠 |
Genome editing for treating autoimmune disease
|
EP3827847A4
(en)
*
|
2018-07-26 |
2023-07-19 |
Toolgen Incorporated |
Gene editing of anticoagulants
|
US20210348177A1
(en)
|
2018-09-05 |
2021-11-11 |
The Regents Of The University Of California |
Generation of heritably gene-edited plants without tissue culture
|
CA3121855A1
(en)
*
|
2018-09-11 |
2020-03-19 |
Board Of Regents, The University Of Texas System |
A genetic mouse model of autoimmune adverse events and immune checkpoint blockade therapy
|
CN112771071A
(en)
|
2018-09-28 |
2021-05-07 |
麻省理工学院 |
Collagen-localized immunomodulatory molecules and methods thereof
|
WO2020072059A1
(en)
*
|
2018-10-04 |
2020-04-09 |
Bluebird Bio, Inc. |
Cblb endonuclease variants, compositions, and methods of use
|
MX2021004214A
(en)
*
|
2018-10-16 |
2021-07-15 |
Intellia Therapeutics Inc |
Compositions and methods for immunotherapy.
|
US20210395784A1
(en)
*
|
2018-10-29 |
2021-12-23 |
China Agricultural University |
Crispr/cas12f enzyme and system
|
EP3898958A1
(en)
|
2018-12-17 |
2021-10-27 |
The Broad Institute, Inc. |
Crispr-associated transposase systems and methods of use thereof
|
US20220096551A1
(en)
*
|
2019-01-28 |
2022-03-31 |
Bar Ilan University |
Combinations, nanoparticles and methods for controlling natural killer cell activation and function
|
CA3128888A1
(en)
|
2019-02-15 |
2020-08-20 |
Editas Medicine, Inc. |
Modified natural killer (nk) cells for immunotherapy
|
MX2021011325A
(en)
|
2019-03-19 |
2022-01-06 |
Broad Inst Inc |
Methods and compositions for editing nucleotide sequences.
|
EP3953485A4
(en)
|
2019-04-10 |
2023-05-17 |
University of Utah Research Foundation |
Htra1 modulation for treatment of amd
|
JP2022531185A
(en)
|
2019-04-30 |
2022-07-06 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
Allogeneic cell therapy for B cell malignancies using CD19 targeting genetically modified T cells
|
KR20220016475A
(en)
|
2019-05-01 |
2022-02-09 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Cells, Associated Polynucleotides and Methods Expressing Recombinant Receptors at the Modified TFTFR2 Locus
|
EP3962519A1
(en)
|
2019-05-01 |
2022-03-09 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
|
WO2020236967A1
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Random crispr-cas deletion mutant
|
MX2021015495A
(en)
*
|
2019-06-14 |
2022-04-18 |
2Seventy Bio Inc |
Compositions and methods for treating cancer.
|
JP2022538974A
(en)
|
2019-06-26 |
2022-09-07 |
マサチューセッツ インスチテュート オブ テクノロジー |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
WO2021041922A1
(en)
|
2019-08-30 |
2021-03-04 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
WO2021150078A1
(en)
*
|
2020-01-23 |
2021-07-29 |
주식회사 강스템바이오텍 |
Off-the-shelf stem cells and immune cells, and pharmaceutical composition comprising same
|
US11896619B2
(en)
|
2020-03-10 |
2024-02-13 |
Massachusetts Institute Of Technology |
Compositions and methods for immunotherapy of NPM1c-positive cancer
|
WO2021216622A1
(en)
|
2020-04-21 |
2021-10-28 |
Aspen Neuroscience, Inc. |
Gene editing of gba1 in stem cells and method of use of cells differentiated therefrom
|
US20230165909A1
(en)
|
2020-04-21 |
2023-06-01 |
Aspen Neuroscience, Inc. |
Gene editing of lrrk2 in stem cells and method of use of cells differentiated therefrom
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
US20210338833A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Chimeric antigen receptor-targeting ligands and uses thereof
|
JP2023525304A
(en)
|
2020-05-08 |
2023-06-15 |
ザ ブロード インスティテュート,インコーポレーテッド |
Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
|
KR20230022868A
(en)
|
2020-05-13 |
2023-02-16 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Method for producing donor-batch cells expressing a recombinant acceptor
|
EP4162052A1
(en)
*
|
2020-06-03 |
2023-04-12 |
Mammoth Biosciences, Inc. |
Programmable nucleases and methods of use
|
JP2023531531A
(en)
|
2020-06-26 |
2023-07-24 |
ジュノ セラピューティクス ゲーエムベーハー |
Engineered T Cells Conditionally Expressing Recombinant Receptors, Related Polynucleotides, and Methods
|
US11332744B1
(en)
|
2020-10-26 |
2022-05-17 |
Arsenal Biosciences, Inc. |
Safe harbor loci
|
EP4240756A1
(en)
|
2020-11-04 |
2023-09-13 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
|
EP4284932A1
(en)
*
|
2021-02-01 |
2023-12-06 |
Epsilen Bio S.r.l. |
Gene silencing
|
JP2024509853A
(en)
|
2021-03-03 |
2024-03-05 |
ジュノー セラピューティクス インコーポレイテッド |
Combination of T cell therapy and DGK inhibitor
|
WO2022204071A1
(en)
|
2021-03-22 |
2022-09-29 |
Juno Therapeutics, Inc. |
Method to assess potency of viral vector particles
|
WO2022215982A1
(en)
*
|
2021-04-05 |
2022-10-13 |
주식회사 셀렌진 |
Guide rna complementary to trac gene and use thereof
|
WO2022232839A1
(en)
|
2021-04-30 |
2022-11-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for improved production of primary cd34+ cells
|
US20230016422A1
(en)
*
|
2021-06-23 |
2023-01-19 |
Crispr Therapeutics Ag |
Engineered cells with improved protection from natural killer cell killing
|
WO2023278811A1
(en)
|
2021-07-01 |
2023-01-05 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
CA3227103A1
(en)
|
2021-07-30 |
2023-02-02 |
Matthew P. GEMBERLING |
Compositions and methods for modulating expression of frataxin (fxn)
|
WO2023010135A1
(en)
|
2021-07-30 |
2023-02-02 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
WO2023077149A1
(en)
|
2021-11-01 |
2023-05-04 |
Sigma-Aldrich Co. Llc |
Electroporation enhancers for crispr-cas systems
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
TW202342498A
(en)
|
2021-12-17 |
2023-11-01 |
美商薩那生物科技公司 |
Modified paramyxoviridae fusion glycoproteins
|
WO2023115041A1
(en)
|
2021-12-17 |
2023-06-22 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae attachment glycoproteins
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023137471A1
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
|
WO2023137472A2
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
|
WO2023150518A1
(en)
|
2022-02-01 |
2023-08-10 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023201133A1
(en)
|
2022-04-14 |
2023-10-19 |
Board Of Regents Of The University Of Nebraska |
Cell therapy for alzheimer's disease
|
WO2023224715A1
(en)
|
2022-05-19 |
2023-11-23 |
Massachusetts Institute Of Technology |
Car cells targeting an inserted ligand
|
WO2023250511A2
(en)
|
2022-06-24 |
2023-12-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
|
WO2024007020A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics, Inc. |
Combination of engineered natural killer (nk) cells and antibody therapy and related methods
|
WO2024015881A2
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for targeted transcriptional activation
|
WO2024040254A2
(en)
|
2022-08-19 |
2024-02-22 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
|
WO2024044655A1
(en)
|
2022-08-24 |
2024-02-29 |
Sana Biotechnology, Inc. |
Delivery of heterologous proteins
|
WO2024054944A1
(en)
|
2022-09-08 |
2024-03-14 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
|
WO2024064642A2
(en)
|
2022-09-19 |
2024-03-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
WO2024064838A1
(en)
|
2022-09-21 |
2024-03-28 |
Sana Biotechnology, Inc. |
Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
|
CN116539885B
(en)
*
|
2023-07-06 |
2023-09-29 |
上海秤信生物科技有限公司 |
Tumor autoantigen/antibody combination for early detection of breast cancer and application thereof
|